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Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most 
patients will experience disease progression during or after first-line chemotherapy 
demonstrating the need for new, effective second-line treatments. The only approved 
second-line therapies for patients without targetable oncogenic drivers are docetaxel, 
gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes 
afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the 
role of antiangiogenic agents have been established as important and effective thera-
peutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase 
inhibitor targeting three angiogenesis-related transmembrane receptors (vascular 
endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). 
Several preclinical and clinical studies have proven the usefulness of nintedanib as an 
anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 
1 trial, which investigated the combination of nintedanib with docetaxel for second-line 
treatment in advanced NSCLC patients. The significant improvement in overall survival 
and the manageable safety profile led to the approval of this new treatment in Europe. 
This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.
Keywords: non-small cell lung cancer, angiogenesis, target therapy, nintedanib, second-line treatment, clinical 
trials
INTRODUCTION
Lung cancer is one of the most common malignancies in the world and is the leading cause of 
cancer-related deaths worldwide, accounting for 1.59 million deaths yearly. In the United States 
alone, an estimated 221,200 new cases of lung cancer were diagnosed in 2015, and 158,040 people 
will die of this disease (1–3). Non-small cell lung cancer (NSCLC) is the most frequent type of lung 
cancer, accounting for more than 80% of all cases, whereas small cell lung cancer represents 15–20% 
(4, 5). Most patients will experience disease progression during or after first-line chemotherapy, and 
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there is a significant unmet need for new, effective second-line 
treatments. Currently, the only approved second-line therapies 
for patients who do not harbor identifiable driver oncogenes, 
such as epidermal growth factor receptor (EGFR) gene mutations 
or anaplastic lymphoma kinase (ALK) gene translocations, are 
docetaxel, gemcitabine, pemetrexed (limited for non-squamous 
NSCLC), and erlotinib (6–9).
The majority of patients with NSCLC do not achieve pro-
longed disease control, and the 5-year survival rate remains poor 
at 18.7% (1). Growing knowledge of NSCLC molecular pathobi-
ology has led to the development of new treatments that target 
specific oncogenes (10) and have changed the natural history of 
the disease with a clear improvement of patient’s survival (11). 
However, it is still characterized by a significantly low survival 
for second-line treatment (12, 13) with a median progression-free 
survival (PFS) from 2 to 3 months and a median survival rarely 
exceeding 8 months (14). The recognition of patients harboring 
EGFR mutations (EGFRm) or EML4-ALK translocation and 
displaying tyrosine kinase inhibitors (TKI) response rates of 
approximately 70% account an essential treatment. With the 
use of molecularly targeted therapies, such as erlotinib (15), 
afatinib (16) for EGFRm, osimertinib (17) for EGFRm T790, and 
crizotinib (18), alectinib, and ceritinib (19, 20) for ALK positive 
(Table 1), a higher response rates and prolonged PFS have been 
obtained when compared to chemotherapy in the first- and 
second-line setting (21).
Antiangiogenic agents have been established as important and 
effective therapeutic targets in many cancers, including NSCLC. 
Angiogenesis is one of the hallmarks of cancer and is critical for 
the growth, progression, and metastasis of many solid tumor 
types (22–24). Mechanisms that support the formation of neo-
vasculature include vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and platelet-derived growth 
factor (PDGF) signaling pathways (22, 25–27). To date, first-line 
bevacizumab remains the only approved antiangiogenic treat-
ment in the therapeutic armamentarium for advanced NSCLC. 
Its use is restricted to patients with tumors with a non-squamous 
histology (28, 29).
In the Eastern Cooperative Oncology Group, 878 patients 
with recurrent or advanced NSCLC were recruited and assigned 
to paclitaxel/carboplatin chemotherapy alone or paclitaxel/car-
boplatin and bevacizumab. The addition of the anti-VEGF to a 
standard, platinum-based doublet regimen conferred a significant 
prolongation in overall survival (OS), PFS, and response rate in 
patients with NSCLC (28) (Table 1). Also, bevacizumab admin-
istered with paclitaxel showed a median PFS longer compared 
to docetaxel in second-third line of treatment (30) In the AVAiL 
trial, patients with non-squamous NSCLC were randomized to 
receive cisplatin/gemcitabine with or without bevacizumab and 
in a similar way, the results in this trial demonstrated an improve-
ment in PFS versus placebo (31).
Furthermore, ramucirumab, a vascular endothelial growth 
factor receptor-2 (VEGFR2) inhibitor, was investigated as 
second-line therapy with docetaxel for stage IV NSCLC. Median 
OS and PFS were longer in the ramucirumab arm compared with 
the placebo arm (32) (Table 1). Even though VEGF is the most 
potent angiogenic molecule, the inhibition of the VEGF pathway 
with TKI or monoclonal antibodies is associated with a modest 
survival benefit.
The multikinases inhibitor sorafenib targets VEGFR2–3, 
PDGFR-β, c-kit, RAF, and FLT-3. In two phase II studies, it was 
determined an improvement in PFS and in OS when used as a 
single agent with respect to placebo (33) (Table 1). Furthermore, 
a phase I/II trial studied the effect of sorafenib combined with 
carboplatin/paclitaxel and showed a median PFS of 34 weeks 
with a good toxicity profile (34). However, two Phase III trials, 
ESCAPE and NEXUS trials, were conducted to confirm the effi-
cacy and feasibility of the combination treatment. Unfortunately, 
neither of the trials met their primary endpoints (35, 36).
Sunitinib, an orally selective multitargeted TKI that inhibits 
PDGFR, KIT, FLT-3, and VEGFR, has also been evaluated in 
combination with both chemotherapy and erlotinib after failure 
of first-line platinum-based chemotherapy. CALGB 30704 ran-
domized patients to pemetrexed alone, sunitinib alone, or the 
combination of pemetrexed/sunitinib as second-line therapy for 
advanced NSCLC (37) (Table 1). The results demonstrated a non-
statistically significant higher response rate in patients receiving 
pemetrexed/sunitinib and a better PFS and OS in the single agent 
pemetrexed arm. Also, two trials evaluated the combination of 
erlotinib and sunitinib, and no differences in PFS or OS were 
observed (38, 39).
Unfortunately, the activation of other angiogenic pathways 
has also developed drug resistance by the tumor. Molecules, 
such as FGF and PDGF, have been found upregulated in patients 
exhibiting acquired resistance to anti-VEGF treatment. The use 
of multitargeted anti-angiogenesis tyrosine kinase inhibitors 
(MATKIs) to achieve simultaneous inhibition of two or three 
angiogenic pathways has been proposed as a promising strategy 
for improved outcomes in NSCLC patients (40).
Nintedanib (Vargatef Ⓡ; BIBF 1120) is a novel, potent, oral, 
triple angiokinase inhibitor that targets VEGF receptors 1 to 3, 
PDGF receptors alpha and beta, and FGF receptors 1 to 3 (41–43), 
as well as members of the Src family and FLT-3 (43) (Figure 1).
PRECLINICAL DEVELOPMENT
Nintedanib was identified during a program for small molecule 
inhibitors of angiogenesis, and studies were extended to various 
solid tumors (43). Recent evidence shows that nintedanib is a 
potent endothelial cell proliferation inhibitor with a good safety 
profile, proven in both in vitro and in vivo studies.
This molecule, an indolinone derivative, occupies the 
adenosine triphosphate-binding sites in the kinase domain 
of pro-angiogenic receptors previously mentioned, inhibiting 
the downstream signaling pathways. Overall, the spectrum is 
fairly restricted (VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1, 2, 3, 
PDGFR-α and β, FLT3, and SRC family member) and has shown 
low cross-reactivity with other human kinases (41, 43, 44). Peak 
plasma concentrations of nintedanib are reached 2–4 h after oral 
administration and have a terminal half-life of 10–15 h. Also, 
it is metabolized largely via hydrolytic cleavage by esterases; 
cytochrome P450 pathways have a minor role in the metabolism 
of the MATKI. The major route of elimination is fecal/biliary 
excretion (45).
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In vitro studies showed that treatment with nintedanib induced 
proliferation arrest and apoptosis in endothelial cells, smooth 
muscle cells, and pericytes, cell types involved in angiogenesis, 
through the inhibition of both AKT and mitogen-activated pro-
tein kinases signaling pathways, resulting in an overexpression of 
the apoptosis marker cleaved caspase-3 (43).
Moreover, in vivo studies performed in human NSCLC xeno-
grafts have confirmed these results. One of the studies showed 
that at well-tolerated doses, nintedanib was highly active and 
demonstrated additive effects in combination with the cytotoxic 
drugs docetaxel or pemetrexed (42). In addition, in another 
study, nintedanib alone and in combination with standard 
chemotherapy showed a potent inhibition of proliferation and 
increased apoptosis of tumor cells in NSCLC xenografts that were 
poor responders to bevacizumab and resistant to platinum dou-
blet chemotherapy (46). It demonstrated rapid changes in tumor 
vessel architecture, such as reduction of vessel permeability and 
perfusion, and microvessel density. Intracellularly, the inhibitory 
effect of nintedanib was found to be markedly sustained, with 
inhibition of VEGF receptor activation for at least 32 h after being 
treated for 1 h with nintedanib, suggesting slow receptor dissocia-
tion kinetics and sustained inhibition (43). There was no associa-
tion with an increased expression of the epithelial mesenchymal 
transition (EMT) markers, a common mechanism of resistance to 
antiangiogenic therapies (46).
Another recent study evaluating the co-treatment of nint-
edanib with small interfering RNAs against six specific genes 
involved in EMT has shown that this molecule is able to do 
a downregulation of SYDE1 and ZEB1, and this sensitizes 
the cell’s response to the drug in terms of EMT reversal (47). 
Additionally, in vitro and in vivo studies have evaluated the toxic 
potential of nintedanib, showing a tolerable safety profile of this 
compound, excluding any severe cardiovascular, respiratory, or 
neurological adverse effects, as well as any mutagenic potential 
of nintedanib (48).
Furthermore, the combination potential of nintedanib 
with PD-1 antagonists was explored in an in vivo combination 
experiments in two syngeneic murine tumor models. The murine 
tumor cell lines CT-26 and 4T1 were injected subcutaneously 
into female mice and subsequently treated with RMP1-14, a 
murine anti PD-1, nintedanib, or RMP1-14/nintedanib. Single 
agent treatment of CT-26 subcutaneous tumors with RMP1-14 
resulted in antitumor effect with treated to control values of 45% 
and nintedanib resulted in a 63%. The combination treatment 
group after 24 days showed a value of 34%. Additionally, the use 
of nintedanib in the anti PD-1 refractory model 4T1 showed a 
synergistic combinatorial antitumor effect. The combination of 
angiogenic and immune checkpoint inhibition is an attractive 
opportunity to improve overall response rates and efficacy based 
on the dual roles of angiogenic factors in blood vessel formation 
and immune regulation (49).
PHASE I AND PHASE II CLINICAL TRIALS
The tolerability of nintedanib has been studied in different kinds of 
neoplasm, such as ovarian cancer, NSCLC, breast cancer, colorec-
tal cancer, urothelial carcinoma, and head and neck cancer (50). In 
a phase I open-label, dose-escalation trial, Doebele et al. studied 
the combination of this MATKI with paclitaxel and carboplatin in 
chemotherapy-naïve advanced NSCLC (51). Twenty-six patients 
enrolled and received nintedanib at the starting dose of 50 mg 
twice daily on days 2–21 in association with 200 mg/m2 paclitaxel 
FIGURE 1 | Mechanism of action of nintedanib in lung cancer treatment.
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and area under the curve 5 of carboplatin on day 1 of each 21-day 
cycle. Overall, 84.6% (n = 22) experienced a partial response or 
stable disease without confirmation, and 26.9% (n = 7) achieved a 
confirmed partial response. The treatment was well tolerated with 
liver enzyme elevations, thrombocytopenia, abdominal pain, and 
rash being the dose-limiting toxicities (DLT) (Table 2).
In another dose-escalation phase I/II trial, 26 patients with 
advanced NSCLC previously treated with first-line platinum-
based chemotherapy, received nintedanib in association with 
pemetrexed. Patients received a starting dose of nintedanib of 
100 mg twice daily on days 2–21 in association with 500 mg/m2 
of pemetrexed on day 1 of a 21-day cycle. Similar to the previ-
ous studies, the resultant maximum tolerated dose (MTD) of 
nintedanib was established at 200 mg twice daily. Moreover, of 
the enrolled patients, 1 had a complete response, 13 had stable 
response, and 8 patients showed progressive disease. The median 
PFS was approximately 5.4 months. A good safety profile was 
confirmed, with fatigue, anorexia, and ALT increase being the 
most frequent grade 3 drug-related adverse events (52) (Table 2). 
Moreover, in a Japanese trial, the same MTD of nintedanib 
(200 mg twice daily) was established and a manageable safety 
profile and similar efficacy results as the previous studies were 
found (53).
Okamoto et al. evaluated in a phase I trial, the combination 
of nintedanib with docetaxel in advanced NSCLC patients who 
had been previously treated. Forty-two patients (17 BSA < 1.5, 
25 BSA ≥ 1.5) were treated. The MTD of nintedanib was 150 and 
200 mg twice daily in patients with BSA less than 1.5 and BSA 
greater than or equal to 1.5, respectively, in combination with 
75 mg/m2 of docetaxel. They found encouraging efficacy results, 
yielding a 73.7% of disease control rate. Furthermore, DLT, all 
grade 3 hepatic enzymes elevations, occurred in only one-third of 
the enrolled patients. All hepatic enzyme elevations were revers-
ible and manageable with dose reduction or discontinuation. The 
main drug-related adverse events included neutropenia (95%), 
leukopenia (83%), fatigue (76%), alopecia (71%), decreased 
appetite (67%), and elevations in alanine aminotransferase and 
aspartate aminotransferase (64%) (40) (Table 2).
Also, a phase II double-blind study assessed the efficacy, safety, 
and tolerability of nintedanib in stage IIIB/IV NSCLC. The 73 
patients recruited tolerated the continuous treatment and had no 
significant difference in efficacy between treatment arms (ninde-
tanib 250 mg twice a day versus 150 mg twice a day). The median 
PFS was 6.9 weeks and the median OS was 21.9 weeks with no 
significant difference between the two groups; the disease control 
rate was 59% (54) (Table 2).
PHASE III TRIALS
The LUME-Lung 1 trial (NCT00805194) is a multinational, rand-
omized, placebo-controlled phase 3 trial that assessed the efficacy 
and safety of the combination of nintedanib and docetaxel in 
patients with stage IIIB/IV NSCLC progressing after first-line 
chemotherapy. Patients were assigned to docetaxel 75 mg/m2 by 
intravenous infusion on day 1 in addition to nintedanib 200 mg 
twice daily orally or matching placebo on days 2–21, every 
3 weeks. The primary endpoint was PFS, which was assessed by 
an independent central review, analyzed by intention to treat after 
714 events in all patients. As key secondary outcome, OS was 
predefined and analyzed on an intention-to-treat basis in a pre-
specified, stepwise, fixed-sequence order: first, in a predefined 
group of patients with adenocarcinoma and poor prognosis (i.e., 
time elapsed since start of first-line therapy of less than 9 months 
until randomization into the trial); second, in patients with 
adenocarcinoma; and finally, in all patients regardless of histol-
ogy. Other secondary outcomes were investigator-assessed PFS, 
tumor response by central review and investigator assessment, 
safety, and tolerability.
The study met its primary endpoint demonstrating a sta-
tistically significant improvement in PFS that translated into a 
21% reduction in risk of progression (55). The PFS according 
to central independent review was significantly longer in nint-
edanib plus docetaxel group than in docetaxel plus placebo group 
(median PFS 3.4 versus 2.7 months; HR 0.79; 95% CI 0.68–0.92; 
p = 0.0019), with a more pronounced benefit in patients with 
adenocarcinoma histology (median PFS 4.2 versus 1.5 months; 
HR 0.68; 95% CI 0.54–0.84; p =  0.0005). Also, the subset of 
patients with adenocarcinoma and poor prognosis had a median 
PFS of 4.2 months in the docetaxel plus nintedanib group versus 
1.6 months in the docetaxel plus placebo group (HR 0.67; 95% CI 
0.43–1.04, p = 0.0725) (56).
Even though, in the total population of patients there was only 
a trend in favoring the combination of docetaxel and nintedanib 
(median OS 10.1 versus 9.1 months; HR 0.94; 95% CI 0.83–1.05; 
p = 0.2720), in adenocarcinoma subgroup there was a significant 
difference in OS (median OS 12.6 versus 10.3 months; HR 0.83; 
95% CI 0.70–0.99; p = 0.0359). Improvement was also observed 
in patients with adenocarcinoma histology and poor prognosis; 
the median OS was longer in the docetaxel plus nintedanib 
group compared with the docetaxel plus placebo group (median 
OS 10.9 months versus 7.9 months; HR 0.75; 95% CI 0.60–0.92; 
p = 0.0073) (56). The intent-to-treat analysis of OS in all studied 
patients showed a 1-month improvement that did not reach 
statistical significance; however, when adjusted to the sum of 
longest diameters of target lesions, a significant OS benefit was 
seen (55).
The tolerability profile was similar to that shown in phase 
I/II clinical trials. The adverse events that were more common 
in the docetaxel plus nintedanib group than the docetaxel plus 
placebo group were: diarrhea, increases of transaminases, nausea, 
decreased appetite, and vomiting, with only a 18.6% requiring 
dose reduction (56). Also, a study determined the impact on 
tumor growth over time as a treatment effect, with a specific focus 
on patients with poor prognosis (i.e., time of progression less than 
9 months and who had progressive disease as best response to 
first-line treatment). The use of nintedanib and docetaxel showed 
a significant reduction in tumor burden and tumor growth over 
time compared to docetaxel in patients with adenocarcinoma 
histology and in the group of patients with the poorest prognosis 
(57) (Table 2).
Furthermore, Heigener et  al. performed an analysis of 
adenocarcinoma population in the LUME-Lung 1 to determine 
if first-line treatment could influence subsequent outcomes for 
nintedanib and docetaxel arm. In the study, the efficacy outcomes, 
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the OS benefit, and the frequency of adverse events were similar 
regardless of prior treatments with taxanes, pemetrexed, or 
bevacizumab (58).
Popat et  al. confirmed LUME-Lung-1 findings in a meta-
analysis of nine studies. They estimated a probability of 70% for 
nintedanib plus docetaxel being the best second-line treatment 
with regard to OS and PFS (59). Based on these findings, the 
European Medicines Agency approved in November 2014 the 
combination of nintedanib with docetaxel for the second-line 
treatment of adenocarcinoma patients (60). Furthermore, using 
patient-reported outcomes [i.e., 30-item European Organisation 
for Research and Treatment of Cancer Core Quality of Life 
(QoL) Questionnaire and its 13-item lung cancer-specific sup-
plement] to complement the objective measures of efficacy and 
safety, this trial allowed the assessment of patients’ subjective 
perception of their symptom burden and health-related QoL. 
This analysis demonstrated that the survival benefits achieved 
in the LUME-Lung 1 trial were not at the expense of patients’ 
QoL. No significant differences in the PRO composites for 
cough, dyspnea, or pain were observed between the treatment 
groups (56).
Moreover, a cohort of NSCLC Mexican patients receiving 
nintedanib with docetaxel demonstrated efficacy and that was 
well tolerated; 81.25% had a partial response and 18.75% had 
stable disease (61). Also, a descriptive trial used the clinical data 
collection of patients with advanced lung adenocarcinoma who 
progressed to first-line treatment plus bevacizumab included 
in the compassionate-use program of nintedanib. The primary 
objective of the study was to describe the characteristics of 
the patients and their tumors, including previous therapies. 
The secondary objectives were to estimate the time under 
nintedanib treatment and the response rate and to evaluate the 
safety of this new treatment in daily clinical practice. From the 
99 patients who were included, the objective response rate was 
53%, stable disease 26.5%, disease progression 16.3%, and 4% 
were non-evaluable. Also, the disease control rate was 79.6%. 
The majority of patients had adequate tolerance, similar to the 
results obtained in LUME-Lung 1, mostly toxicities grades 1–2. 
However, the retrospective design of the study and the biased 
criteria of the investigator could have influenced in the overes-
timated responses (62).
Another phase III controlled randomized trial, LUME-Lung 2 
(NCT00806819) evaluated the use of nintedanib in combination 
with pemetrexed (500 mg/m2) and compared with pemetrexed 
(500  mg/m2) plus placebo in patients with advanced, non-
squamous NSCLC previously treated with chemotherapy (63). 
The primary endpoint was the same as LUME-Lung 1, while the 
secondary endpoints included OS, investigator-assessed PFS, 
response rate, safety, and QoL. Even though the enrollment 
was halted after randomizing 713 patients based on a planned 
futility analysis, the study met its primary endpoint. The nint-
edanib arm had a significant better PFS (median PFS 4.4 versus 
3.6 months compared with placebo; HR 0.83; 95% CI 0.70–0.99; 
p = 0.0435); however, this difference was not translated into an 
OS benefit (12.2 versus 12.7 months; HR 1.03; 95% CI 0.85–1.24; 
p =  0.7921). Moreover, disease control was also significantly 
improved in the nintedanib arm (61 versus 53%, odds ratio 
1.37, p = 0.039). Also, in this study, nintedanib showed a higher 
incidence of grade 3 increases in liver enzymes and gastrointes-
tinal events, which resolved with dose reduction and supportive 
treatment (56). In contrast to other antiangiogenic agents, no 
grade 3/4 hypertension or hand-foot syndrome was reported 
(54) (Table 1).
Additionally, the association between plasma levels of VEGF, 
FGF, and PDGF was evaluated, both baseline and after treatment 
with nintedanib plus docetaxel, as well as disease control rate, PFS, 
and OS, among 38 patients with NSCLC. A higher percentage 
change reduction in PDGF after treatment was associated with a 
longer PFS and a higher percentage change in FGF was associated 
with a longer OS. Also, a higher reduction of plasma levels of FGF 
and PDGF was associated with better clinical outcomes (64).
Several clinical trials involving nintedanib are ongoing, 
including a phase III study (NCT02299141), that will evaluate 
the effectiveness of nintedanib in molecularly selected NSCLC 
patients and investigate the potential role of some genes 
(VEGFR1-3, PDGFR-A, PDGFR-B, and FGFR1-3) that might be 
involved in the regulation of mechanisms of acquired resistance 
to antiangiogenic agents. Results are expected by June 2017.
CONCLUSION
Nintedanib might be a good treatment option that fulfils the 
unmet need for effective, well-tolerated treatment options in 
advanced NSCLC and alleviate the disease burden for a broad 
selection of patients. The significant improvement in PFS in the 
overall population and the subgroup of patients with adenocarci-
noma observed with the addition of nintedanib to cytotoxic drug 
therapy represents an attractive second-line treatment option. 
Moreover, the safety profile of this MATKI is manageable, giving 
this new treatment option great potential as an emerging combi-
nation for the management of NSCLC.
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